Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circadian Technologies has initiated the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100.
Subscribe to our email newsletter
VGX-100 is a human antibody that acts against the human VEGF-C protein and is indicated in the treatment for cancers, particularly glioblastoma and metastatic colorectal cancers.
The company is developing VGX-100 for a number of other cancer indications, as well as an agent to treat front-of the-eye diseases.
The trial is intended to evaluate the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also when used in combination with other anti-angiogenic agents.
Circadian CEO Robert Klupacs said the company has completed the translation of VGX-100 from early discovery to the clinical development stage.
"Commencing clinical trials with VGX-100 is an extremely important achievement for Circadian and a major step in our goal to develop VGX-100 as a new therapeutic agent in the fight against cancer," Klupacs added.
The company is likely to announce the results in the second half of 2012.